# Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Source: https://onco.cc/trials/nct04130516/  
OnCo record `nct04130516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LNS8801 and Pembrolizumab in advanced solid tumours, run by Linnaeus Therapeutics, Inc., active and no longer recruiting.

## Summary

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab is a phase 1/2 interventional study registered as NCT04130516 by Linnaeus Therapeutics, Inc., with 200 participants enrolled, started 2019-10-21 and due to reach its primary completion in 2026-06-30. Interventions recorded: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER and Pembrolizumab - anti-PD-1 antibody.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04130516
- Phase: 1/2
- Setting: A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
- Sponsor: Linnaeus Therapeutics, Inc.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT04130516: https://clinicaltrials.gov/study/NCT04130516

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [LNS8801](https://onco.cc/drugs/lns8801/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04130516.json